Humanin tracker
Educational reference for Humanin. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
1 h
Tmax
0.5 h
Category
peptide
> PLACEHOLDER — pending clinical review by licensed pharmacist. Humanin is a 24-amino-acid mitochondrial-encoded peptide with cytoprotective properties identified through screening for factors that rescue neurons from Alzheimer's-disease-related toxicity. It signals through a complex involving FPRL1 (formyl peptide receptor-like 1) and the IL-6 receptor beta-subunit (gp130), activating downstream survival pathways. Its half-life is approximately 1 hour. Despite promising preclinical data in neurodegeneration and metabolic disease models, human clinical data remain very limited. Tracking dosing, formulation, and subjective outcomes is critical for users experimenting with this peptide.
Mechanism
A mitochondrial-derived peptide encoded within the mitochondrial genome. In preclinical research it has been associated with cytoprotective and metabolic signaling; the mechanism and relevance in humans are still being characterized.
Research summary
Evidence is largely preclinical and mechanistic, exploring roles in cellular stress, metabolism, and aging biology. It is not an FDA-approved drug, and human clinical trial data are limited. Claims should be read against that evidence gap.
Dosing in the literature
There is no established human clinical regimen and human pharmacokinetics are not well characterized. This summary does not provide dosing.
Reported side effects
Controlled human safety data are limited, so the side-effect and long-term safety profile is largely unknown. Sourcing and purity are recurring quality concerns.
Stacking notes
Discussed in longevity and metabolic-research contexts, sometimes alongside other mitochondrial-derived peptides; there is no controlled human evidence supporting specific combinations.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Humanin mitochondrial-derived peptide review · peer-reviewed review article (2016)predominantly preclinical evidence; search PubMed for humanin peptide
- Regulatory status note · FDA / regulatory guidance (2024)not an approved drug; verify current status
References
- Humanin reviewDOI: 10.1016/j.tem.2013.06.001
Track Humanin in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.